Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BeOne Medicines develops and sells targeted cancer drugs that help patients fight tumors around the world.
BeOne Medicines makes medicine for people with cancer. Its job is to design drugs that attack cancer cells while doing less harm to the rest of the body, and then to get those drugs approved and sold in countries around the world.
Its biggest product is Brukinsa, a pill for certain blood cancers such as chronic lymphocytic leukemia. Brukinsa is the engine of the whole company: it brings in most of the money and funds everything else. The company also sells Tevimbra, a drug that helps the immune system attack tumors, and Pamiparib, a treatment for certain ovarian and other cancers. Hospitals, doctors, and health insurers ultimately pay for these drugs, and patients get them by prescription. Doctors choose them because they work well and are often easier to take than older options鈥擝rukinsa, for example, is a simple daily pill rather than an infusion. BeOne is a serious player now, not a scrappy startup. Brukinsa goes head-to-head with older blockbuster blood-cancer drugs, most notably Imbruvica from AbbVie and Johnson & Johnson, and it has taken real market share from them. The company has grown fast and is now profitable, which is rare for a cancer-drug maker of its age. It also runs a large global clinical trial operation and sells in major markets including the United States, Europe, and China.
The backstory is worth knowing. The company was founded in Beijing in 2010 and built itself around one bet: that a better blood-cancer drug could beat the established giants. It worked, and the company grew into a global business. In 2025 it rebranded from BeiGene to BeOne Medicines and moved its legal home to Switzerland, a change meant to reflect that it is now a worldwide company rather than a China-first one. One thing to watch: a lot of its growth and manufacturing still runs through China, so shifts in U.S.鈥揅hina trade and drug-pricing rules are a genuine risk to the business.
Saved answer 路 last researched 12 Nov 2026